Patent Board Nixes Tribe’s Sovereign Immunity Defense For Patent Review
(February 27, 2018, 12:47 PM EST) -- WASHINGTON, D.C. — A drugmaker cannot shield its patents from federal review by using an Indian tribe’s sovereign immunity, the U.S. Patent Trial and Appeal Board held Feb. 23 (Mylan Pharmaceuticals...
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login